Komen reality not in Dallas

Article

While it appears that the big news about Susan G. Komen for the Cure is coming from Dallas, it's not. The big news is coming from the organization's 119 affiliates, and right now I can envision the small groups of women and men who run these local affiliates sitting with head in hands as they think about what programs will lose funding from the trickle down of the national foundation's debacle. Yes, the Komen foundation is a mess right now with its leadership dropping like flies. With the newest announcement that Nancy Brinker is leaving (which should have happened months ago), I hope they can find another Susan Braun, the woman who led them for 9 years to a position of integrity in the foundation world. But forget all that for a minute. The bigger story here is with the group's affiliates, which are found in cities small and large around the country. In many cases, the funds raised from these affiliates provide the only breast health education and screening available in the area. Funds from local affiliates have bought mammography machines for hospitals or funded programs to bring mammography to rural or underserved women of all kinds. It has funded treatment for women who could not have received it. In the early '90s I was part of a nonproft called The Bridge, which brought together doctors and advocates to help provide timely treatment for uninsured women. We would never have gotten off the ground if the Dallas affiliate of Komen had not funded us, and when they did, it was a stamp of approval for other organizations who knew that the affiliate researched any group it funded. Remember that 75% of the funds raised by affiliates stay local for programs in the community of the affiliate. Those funds mean the difference between life and death for many women. I have spoken at events for many of these affiliates, and I can tell you that these are the hardest working women and men in breast cancer today. They work full time jobs and work another full time job fundraising to support programs for the needs of women in their area. They are driven by their own experience or that of a loved one. They are not driven by politics but by the need to make a difference. Instead of all the negative about Komen national, let's hear from those of you working in the affiliates. Tell us what you are doing in your community. Tell us how a Komen affiliate has made a difference to you or your program.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content